ABBV · 10-Q · 2026Q2 · Full report
Market Demand Trends
AbbVie Inc. · 2026-08-03 · Importance 34 · Surprise 64 · In source text
Skyrizi and Rinvoq continued to gain market share across all indications, with six-month net revenues increasing 26% and 22%, respectively, on a constant-currency basis. Vraylar, Botox Therapeutic, Ubrelvy, Qulipta and Vyalev also benefited from market growth, demand and/or market-share uptake, with Qulipta and Vyalev increasing 39% and more than 100%, respectively. Humira declined 38% due to direct biosimilar competition following loss of exclusivity, while Imbruvica declined 27% because of unfavorable U.S. pricing, lower U.S. demand and reduced collaboration revenues. Juvederm Collection declined 5% for the six months due to decreased consumer demand and unfavorable pricing, whereas Botox Cosmetic increased 10%, driven partly by consumer demand in certain international markets.
Key facts
- Humira total net revenues decreased 36% for the three months and 38% for the six months ended June 30, 2026 at constant currency, primarily due to direct biosimilar competition after loss of exclusivity. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | — | Humira total net revenues decreased 36% for the three months and 38% for the six months ended June 30, 2026 at constant currency,… |
| revenue | negative | realized | — | Humira total net revenues decreased 36% for the three months and 38% for the six months ended June 30, 2026 at constant currency,… |